5-Amino-1MQ is a small-molecule inhibitor of the enzyme NNMT, studied primarily for its effects on fat metabolism, body weight, and cellular energy in rodent models.
What it does
5-Amino-1MQ blocks an enzyme called NNMT (nicotinamide N-methyltransferase), which normally converts nicotinamide — a building block of NAD+ — into a waste metabolite. NAD+ is the molecule cells use to run energy metabolism and activate sirtuins (proteins that regulate cellular repair and mitochondrial function). When NNMT is overactive, as it tends to be in obesity and metabolic syndrome, less nicotinamide reaches the NAD+ salvage pathway. Blocking NNMT with 5-Amino-1MQ frees up that nicotinamide, raising intracellular NAD+ levels and improving mitochondrial output al. 2021.
NNMT also consumes SAM (S-adenosylmethionine), the body's primary methyl donor. SAM is needed for DNA methylation, histone modification, and neurotransmitter synthesis. By inhibiting NNMT, 5-Amino-1MQ preserves the SAM pool for those downstream functions al. 2021. This NNMT–NAD+–SAM axis sits at the intersection of obesity, epigenetics, and metabolic regulation PubMed 34267879 PubMed 34704059.
A third effect is direct: NNMT inhibition reduces adipogenesis — the process by which precursor cells differentiate into fat cells — and limits lipid accumulation in white adipose tissue. Notably, in mouse studies the body-weight reduction occurred without any drop in food intake, pointing to increased energy expenditure rather than appetite suppression al. 2021.
What the evidence shows
Body weight and fat loss Moderate rodent evidence; no published human trials
The most direct evidence comes from a 2021 study showing that pharmacological NNMT inhibition reduced adiposity and body weight in mice without suppressing food intake, implying a genuine increase in metabolic rate al. 2021. NNMT is consistently found to be upregulated in white adipose tissue in obese animals and humans, which provides a plausible biological rationale, but no controlled human trials have tested 5-Amino-1MQ specifically for fat loss. Current human data are limited to self-reported protocols.
NAD+ augmentation and metabolic function Strong mechanistic evidence in vitro and in rodents; no direct human data
By redirecting nicotinamide toward NAD+ synthesis, NNMT inhibition raises cellular NAD+ and increases sirtuin activity — a pathway also targeted by NMN and NR supplementation. Macrocyclic peptide NNMT inhibitors have confirmed this mechanism at the cellular level PubMed 34267879 PubMed 34704059. A 2024 mouse study found NNMT inhibition improved cardiac function and structure in a heart-failure-with-preserved-ejection-fraction model, suggesting metabolic benefits extend beyond adipose tissue PubMed 40484359.
Cancer biology (research context) Preclinical only — not a therapeutic use case for self-administration
Multiple preclinical studies have identified NNMT as a driver of cancer cell survival and metastasis. NNMT overexpression enhances radiation resistance in cancer stem cells PubMed 21719135, promotes peritoneal metastasis in gastric cancer PubMed 33508890, and supports immune-suppressive M2 macrophage polarization in gallbladder carcinoma PubMed 36633260. NNMT also appears to enhance invasiveness in keloid fibroblasts PubMed 40818625. These findings motivate interest in NNMT inhibition as an oncology adjunct, but this is strictly a research-stage question — not a basis for self-use.
How it's used
In studies and self-reported protocols, oral doses range from 50 mg/day at the low end to 200 mg/day at the high end, with 100–150 mg/day being the most commonly reported range. The half-life is approximately 6 hours. Most self-reported protocols dose once daily in the morning. Unlike many compounds in this space, 5-Amino-1MQ is taken orally rather than injected. No human pharmacokinetic trials have formally established dose ranges, so the figures above are extrapolated from rodent studies and anecdotal human reports.
Side effects and safety
Reported side effects in self-reported human use are mild and include nausea, headache, and general GI discomfort; fatigue has been noted at higher doses. No severe adverse events have been documented in the published literature for this specific compound. Because NNMT also plays roles in fibrosis regulation PubMed 35107844 and immune modulation PubMed 36633260, the long-term consequences of sustained inhibition in humans are genuinely unknown. The compound is contraindicated in pregnancy. No long-term human safety data exist — this is a significant gap, not a minor caveat.
Bottom line
5-Amino-1MQ has a coherent and well-supported mechanism in rodents, and the fat-loss results in mouse models are real and notable al. 2021. The honest summary is that no human trials have tested it, so anyone using it is operating well ahead of the clinical evidence. It may appeal to people already exploring NAD+ precursor strategies who want to work on the enzyme side of the equation, but the absence of human safety data means the risk profile is genuinely uncertain.